SRC and melanoma: In 2008, Eustace et al. showed that Src inhibition by dasatinib induces growth impairment, inhibits invasion/migration, favors apoptosis/G1 arrest, and enhances response to chemotherapy (temozolomide) in melanoma lines (Table 1) [57].